Wen Si

Wen Si

Auto-generated profile, based on publicly available information

Wen Si

Peking University 1 Biomedical Pioneering Innovative Center (BIOPIC), Academy for Advanced Interdisciplinary Studies, School of Life Sciences, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Science
Verified
Journal Article
Closed access
LZLiangtao Zheng
Liangtao Zheng
SQShishang Qin
Shishang Qin
WSWen Si
Wen Si
AWAnqiang Wang
Anqiang Wang
BXBaocai Xing
Baocai Xing
ZZZemin Zhang
Zemin Zhang
An atlas of cancer-associated T cells: The tumor microenvironment contains many different kinds of immune cells, the composition, function, and roles of which are unclear. Using single-cell RNA sequencing of T cells in 21 cancer types from more than 300 patients, Zheng et al . identified differences in transcript composition that could be used to catalog different T cell types (see the Perspective by van der Leun and Schumacher). These annotations identified the different roles of specific types of CD4 + and CD8 + T cells among the different tumor types. Some of these clusters revealed evidence for two developmental paths for T cells, one of which shows a trajectory toward the “exhausted” T cell state, knowledge of which may be useful in developing future cancer immunotherapies. —LMZ

1 August 2020 in Immunity
Verified
Journal Article
Closed access
WLWentao Li
Wentao Li
SQShizhen Qiu
Shizhen Qiu
JCJian Chen
Jian Chen
SJShutan Jiang
Shutan Jiang
WCWendong Chen
Wendong Chen
HWHaopeng Wang
Haopeng Wang

27 January 2026 in Cancer Research
Verified
Journal Article
Open access
LQLu Qi
Lu Qi
GDGuohui Dang
Guohui Dang
XLXinnan Ling
Xinnan Ling
YMYuhui Miao
Yuhui Miao
YBYufei Bo
Yufei Bo
LZLinnan Zhu
Linnan Zhu
Cancer-associated fibroblasts (CAF) play a crucial role in shaping the tumor microenvironment and driving tumor progression. Although single-cell transcriptomics has revealed the phenotypic and functional heterogeneity of CAFs, effective therapeutic strategies targeting CAFs remain urgently needed. In this study, we identified LRRC15+ CAFs as a tumor-specific CAF subset in lung cancer and proposed LRRC15 as a potential therapeutic target. LRRC15 deficiency suppressed lung cancer progression in mice by modulating macrophage polarization and enhancing CD8+ T-cell activation. Mechanistically, LRRC15 deficiency inhibited CD206+ macrophage polarization by reducing extracellular matrix (ECM) production in CAFs, leading to increased CD8+ T-cell cytotoxicity. Finally, development of a bispecific antibody targeting LRRC15 and TGFβ enabled effective downregulation of LRRC15 expression in CAFs and limited tumor progression in mice. This study highlights LRRC15 as a promising therapeutic target and provides insights into CAF-directed cancer treatment strategies. Significance: LRRC15 in cancer-associated fibroblasts enhances extracellular matrix deposition, facilitates M2 macrophage polarization, and suppresses CD8+ T cell–mediated immunity, thereby promoting lung cancer progression and representing a potential therapeutic target.


17 June 2026
Verified
Other
Open access
LQLu Qi
Lu Qi
GDGuohui Dang
Guohui Dang
XLXinnan Ling
Xinnan Ling
YMYuhui Miao
Yuhui Miao
YBYufei Bo
Yufei Bo
LZLinnan Zhu
Linnan Zhu
Figure S5 Lrrc15 expression in CAFs promotes mouse macrophage M2 polarization in vitro, related to Figure 4

17 June 2026
Verified
Other
Open access
LQLu Qi
Lu Qi
GDGuohui Dang
Guohui Dang
XLXinnan Ling
Xinnan Ling
YMYuhui Miao
Yuhui Miao
YBYufei Bo
Yufei Bo
LZLinnan Zhu
Linnan Zhu
Figure S7 LRRC15 in CAFs promotes macrophage M2 polarization via ECM, related to Figure 5